528MO Is re-introduction or continuation of PARP inhibitors after local therapy for oligo-metastatic progression in patients with relapsed ovarian cancer relevant?

MLA

G. Thibault, et al. “528MO Is Re-Introduction or Continuation of PARP Inhibitors after Local Therapy for Oligo-Metastatic Progression in Patients with Relapsed Ovarian Cancer Relevant?” Annals of Oncology, vol. 33, Sept. 2022, pp. S787–88. EBSCOhost, https://doi.org/10.1016/j.annonc.2022.07.656.

APA

G. Thibault, M. Kfoury, D. Lorusso, A. Floquet, J. Ventriglia, H. Salaun, M. Moubarak, R. Rivoirard, L. Polastro, L. Favier, B. You, D. Berton-Rigaud, T. De La Motte Rouge, L. Mansi, C. Abdeddaim, K. Prulhiere, L. Lancry Lecomte, M. Provansal Gross, C. Dalban, & I.L. Ray-Coquard. (2022). 528MO Is re-introduction or continuation of PARP inhibitors after local therapy for oligo-metastatic progression in patients with relapsed ovarian cancer relevant? Annals of Oncology, 33, S787–S788. https://doi.org/10.1016/j.annonc.2022.07.656

Chicago

G. Thibault, M. Kfoury, D. Lorusso, A. Floquet, J. Ventriglia, H. Salaun, M. Moubarak, et al. 2022. “528MO Is Re-Introduction or Continuation of PARP Inhibitors after Local Therapy for Oligo-Metastatic Progression in Patients with Relapsed Ovarian Cancer Relevant?” Annals of Oncology 33 (September): S787–88. doi:10.1016/j.annonc.2022.07.656.